FDA CRL - EVOLUS INC

The FDA issued a Complete Response Letter (CRL) to Evolus, Inc. regarding its Biologics License Application (BLA 761085) for botulinum toxin Type A injection, originally submitted on May 15, 2017, under section 351(a) of the Public Health Service Act. The agency determined the application could not be approved due to significant product quality deficiencies concerning both the drug substance (DS) and drug product (DP).Major issues included insufficient data and validation for microbial control, purity, and endotoxin testing of the DS, specifically lacking details on *Clostridium botulinum* purity, vegetative cell monitoring, in-process bioburden, and established endotoxin limits. For the DP, the FDA identified concerns with endotoxin reduction validation, container closure integrity testing (insufficient worst-case parameters and missing positive controls for bacterial ingress detection), unsupported sterile hold times, and absence of low endotoxin recovery testing or routine bioburden monitoring.Additionally, Evolus's DS reference material program lacked sufficient quantities and stability monitoring. The proposed post-approval stability protocol was deemed inadequate for removing crucial testing time points (3, 6, 9, and 18 months), contrary to ICH QSC guidelines. The company also needed to clarify the delegation of quality responsibilities for lot release to a "soon to be established distributor."Evolus is required to provide comprehensive validation data, establish appropriate limits, update test methods and stability protocols, revise quality management procedures, and submit a complete list of all unsolicited changes made to the BLA after its initial submission.